Evidence map›Paper›PMID 42286395›Full record

ReviewVirus genes2026

Reverse genetics strategies for coronaviruses: platform construction and applications in vaccine development.

Yuhang Jia, Xinyu Han, Yuchen Ma, Xinjuan Wang, Yunzhu Yang, Aohan Zhang, Ke Ding, Songbiao Chen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Virus genes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yuhang Jia *Laboratory of Functional Microbiology and Animal Health, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, 471003, People's Republic of China.
Xinyu Han *Laboratory of Functional Microbiology and Animal Health, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, 471003, People's Republic of China.
Yuchen MaLaboratory of Functional Microbiology and Animal Health, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, 471003, People's Republic of China.
Xinjuan WangLaboratory of Functional Microbiology and Animal Health, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, 471003, People's Republic of China.
Yunzhu YangLaboratory of Functional Microbiology and Animal Health, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, 471003, People's Republic of China.
Aohan ZhangLaboratory of Functional Microbiology and Animal Health, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, 471003, People's Republic of China.
Ke DingMinistry of Education Key Laboratory for Animal Pathogens and Biosafety, Zhengzhou, 450000, People's Republic of China. keding19@163.com.
Songbiao ChenLaboratory of Functional Microbiology and Animal Health, College of Animal Science and Technology, Henan University of Science and Technology, Luoyang, 471003, People's Republic of China. chensongbiao@126.com.

Funding

the Science and Technology Research Project of Henan Province 252102111004Xinxiang Major Science and Technology Special Project ZDYF202605
6 · The paper itself

Abstract

The continuous emergence of novel coronaviruses, characterized by high mutation rates and frequent recombination events, poses severe threats to global "One Health." Notably, the recent outbreak of the recombinant feline coronavirus (FCoV-23) and the persistence of SARS-CoV-2 variants underscore the urgent need to understand viral pathogenesis and cross-species transmission mechanisms. Reverse genetics technology serves as a critical platform for bridging genomic sequencing to functional virology, enabling targeted mutagenesis and the generation of recombinant viruses. However, the construction of reverse genetics systems for coronaviruses is often hampered by their exceptionally large genomes and the instability of viral cDNA sequences in bacterial hosts due to cytotoxicity. This review moves beyond a simple enumeration of methods to systematically compare current reverse genetics strategies-including in vitro ligation, bacterial artificial chromosome (BAC) systems, and transformation-associated recombination (TAR)-across different viral genera. Furthermore, we critically evaluate the application of these platforms in deciphering pathogenic mechanisms and developing next-generation vaccines, with a specific focus on overcoming technical bottlenecks and designing broad-spectrum countermeasures against emerging cross-species threats.

Indexed as

CoronavirusCoronavirus InfectionsReverse GeneticsVaccine DevelopmentViral VaccinesAnimalsChromosomes, Artificial, BacterialCOVID-19Genome, ViralHumansRecombination, GeneticSARS-CoV-2Viral VaccinesApplicationsConstruction strategiesCoronavirusReverse genetics systemVaccine

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.